Galena Pharma Revenue and Competitors

Kuopio,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Galena Pharma's estimated annual revenue is currently $2.5M per year.(i)
  • Galena Pharma's estimated revenue per employee is $98,000

Employee Data

  • Galena Pharma has 25 Employees.(i)
  • Galena Pharma grew their employee count by 14% last year.

Galena Pharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$14.1M1015%N/AN/A
#2
$1.6M19-71%N/AN/A
#3
$212.8M10635%$65MN/A
#4
$6.8M548%N/AN/A
#5
$12.9M922%$23.1MN/A
#6
$1M12N/AN/AN/A
#7
$106.5M599-17%$2.3MN/A
#8
$35.6M2316%N/AN/A
#9
$38.3M2495%N/AN/A
#10
$45M299-4%$102.6MN/A
Add Company

What Is Galena Pharma?

Galena Pharma Oy is a Finnish pharmaceutical factory specialising in contract manufacturing and packaging services. Our production facilities in Kuopio manufacture various products relating to health and well-being under contract: pharmaceuticals, medical devices, nutritional supplements, cosmetics, animal care products and sports products.

keywords:N/A

N/A

Total Funding

25

Number of Employees

$2.5M

Revenue (est)

14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Galena Pharma News

2022-04-19 - Cancer Vaccines Market Size, Analysis By Growth Rate ...

ImmunoBiology Ltd. Galena Biopharma. Table of Content: Market Definition and Overview; Research Method and Logic; Market Competition Analysis...

2022-04-17 - Essential Thrombocythemia Drug Market Size, Outlook And ...

... Aop Orphan Pharmaceuticals AG, F. Hoffmann-La Roche Ltd, Galena Biopharma Inc, Incyte Corp, Italfarmaco SpA, MEI Pharma Inc, PharmaEssentia Corp.

2022-04-13 - Global Immuno-Oncology Drugs Market Report 2022 - Featuring Amgen, AstraZeneca and AbbVie Among Others - ResearchAndMarkets.com

Galena Biopharma. Bavarian Nordic. Celldex Therapeutics. ImmunoCellular Therapeutics. Takeda. Spectrum Pharmaceuticals. GlaxoSmithKline.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.3M30-23%N/A
#2
N/A3559%N/A
#3
$8.4M390%N/A
#4
$12.7M6724%N/A
#5
N/A7032%N/A